NASDAQ · Biotechnology

CAPR (CAPR) Stock

$3.93 -5.76% NASDAQ: CAPR Healthcare

Valuation

MetricValue
Price$3.93
Market Cap$227.59M
P/E Ratio-50.70
P/B Ratio5.91
P/S Ratio81.76
EPS (TTM)$-2.26
52-Week High$40.37
52-Week Low$3.93
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-46.56%
ROA-25.68%
ROCE-35.29%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio9.01

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$3.0M$25.0M$22.0M$0
Operating Profit$-21.0M$-30.0M$-24.0M$-43.0M$-108.0M
Net Profit$-20.0M$-29.0M$-22.0M$-40.0M$-105.0M
EPS$-0.87$-1.18$-0.83$-1.15$-2.26
Op Margin-8549.9%-1163.9%-95.6%-191.1%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$41.0M$50.0M$59.0M$170.0M$356.0M
Total Liabilities$10.0M$38.0M$36.0M$25.0M$50.0M
Cash$35.0M$10.0M$15.0M$11.0M$288.0M
Borrowings$3.0M$3.0M$2.0M$1.0M$21.0M

Latest News

CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review Stocktwits · Jun 30, 2026 Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy MT Newswires · Jun 29, 2026 Capricor’s Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch – CAPR Stock Slides 11% Stocktwits · Jun 26, 2026 Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire · Jun 26, 2026 Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference GlobeNewswire · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-17.0M$5.0M$-26.0M$-40.0M$-69.8B
Investing Cash Flow$-2.0M$-38.0M$3.0M$-118.0M$94.6B
Financing Cash Flow$0$0$0$0$248.6B
Net Cash Flow$2.0M$-25.0M$5.0M$-3.0M$276.6B
Free Cash Flow$-18.0M$2.0M$-28.0M$-42.0M$-72.7B

Valuation & Return Ratios

MetricValue
PEG Ratio0.38
EV / EBITDA-14.20
FCF Yield-5046.21%
Quick Ratio8.88
Interest Coverage-36.00
Return 1Y190.76%
Return 3Y338.72%
Return 5Y377.60%

Ownership

Insiders Held9.47%
Institutions Held59.73%
Institutions Float Held65.98%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC3,818,6002026-03-31
Blackrock Inc.3,421,8152026-03-31
Tang Capital Management, LLC3,399,9002026-03-31
State Street Corporation2,181,9012026-03-31
Vanguard Capital Management LLC2,027,7322026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACHV $6.66 +2.94% -4.63 $683.71M 0.00%
ALLO $1.95 +2.63% -2.17 $673.05M 0.00%
ARCT $6.26 +0.64% -2.93 $177.93M 0.00%
CABA $2.71 -2.17% -2.23 $441.88M 0.00%
EDIT $2.62 -2.24% -1.39 $256.50M 0.00%

About CAPR

CAPR is led by CEO Linda Marbán, employs 160 people, headquartered in US, publicly traded since 2007.

CAPR stock trades at $3.93 with a market capitalization of $227.59M. The stock is valued at a price-to-earnings (P/E) ratio of -50.70, price-to-book of 5.91, price-to-sales of 81.76. Over the past 52 weeks the stock has ranged between $3.93 and $40.37, and currently trades 90.3% below its 52-week high.

On profitability, CAPR generates a return on equity (ROE) of -46.56%, return on capital employed of -35.29%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides